TLDR:
- Rapport Therapeutics, backed by Johnson & Johnson’s venture capital arm, has filed for a US IPO.
- The company develops small molecule medicines for central nervous system disorders.
Biopharmaceutical company Rapport Therapeutics, supported by Johnson & Johnson’s venture capital arm, has filed for an initial public offering in the United States. The company focuses on developing small molecule medicines for patients suffering from central nervous system disorders. Rapport plans to use a portion of the IPO proceeds to advance the clinical development of its lead product candidate, RAP-219, for the treatment of focal epilepsy, a common neurological disease affecting millions worldwide. The company’s investors include prominent firms like ARCH Venture, Cormorant Asset Management, Fidelity, and Third Rock Ventures. Since its inception in 2022, Rapport has raised about $250 million in equity capital from life sciences investors. The company’s net loss widened in 2023, and it aims to list on the Nasdaq under the symbol “RAPP” with underwriters including Goldman Sachs, Jefferies, TD Cowen, and Stifel.
